Left to right: Laura Occhiuzzi, Pete Knox, Alyssa O’Driscoll, Sarcoma Alliance, Annie Achee, National LeioMyoSarcoma Foundation, Denise Reinke, SARC, and Mitch Achee, National LeioMyoSarcoma Foundation. GIST Research from CTOS 2018 A web-based [...]
In a pre-print electronic publication of the July 7, 2016 edition of Clinical Cancer Research, a team of Italian researchers examined the link between “Quadruple-Negative” GISTs (those that do not exhibit KIT, PDGFRA, or BRAF [...]
Dr. Alexander Drilon of Memorial Sloan Kettering Cancer Center recently reported at AACR on a potential new cancer treatment, Entrectinib, a receptor tyrosine kinase (RTK) inhibitor developed to target tumors carrying NTRK1, NTRK2, NTRK3, [...]
Genetic Alliance recently held an event in Chapel Hill, N.C. that brought together patient advocates, scientists and representatives from the pharmaceutical industry in a unique “speed-dating” format. Disease advocacy organizations were invited to present briefly [...]
A recent study further documented the advantage of three years of adjuvant imatinib versus one year in high-risk GIST patients. The study, which is to be published in the Journal of Clinical Oncology, was authored by [...]
In an online article, Peter Pitts, a former FDA associate commissioner, discussed the topic of off-label product claims by pharmaceutical companies. Off-label use in this case refers to using a medication for an intention [...]
In a recent study led by Danielle A Bischof, MD of Johns Hopkins and published in JAMA Surgery, the authors propose a new way of estimating disease-free survival for GIST patients – Conditional Disease-free Survival [...]
A recent roundtable discussion at the National Comprehensive Cancer Network’s (NCCN) 20th Annual Conference opened up a discussion on treatment costs and introduced the proposed use of evidence blocks to compare treatments. Currently, the [...]
The LRG is proud to announce that the inaugural class of our GIST Expert Patient Training Program has been completed. The class, which was open to GIST patients, caregivers, and other members oaf the extended GIST community, was comprised of just under 20 students and was a comprehensive offering designed to help participants better understand the science behind GIST.
The Life Raft Group is pleased to announce the release of the first issue of The GIST Cancer Journal, the official journal of the Life Raft Group and the first academic journal devoted solely to GIST.
